CA2741117A1 - Biomarkers for heart failure - Google Patents

Biomarkers for heart failure Download PDF

Info

Publication number
CA2741117A1
CA2741117A1 CA2741117A CA2741117A CA2741117A1 CA 2741117 A1 CA2741117 A1 CA 2741117A1 CA 2741117 A CA2741117 A CA 2741117A CA 2741117 A CA2741117 A CA 2741117A CA 2741117 A1 CA2741117 A1 CA 2741117A1
Authority
CA
Canada
Prior art keywords
vegfb
levels
patient
pgf
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2741117A
Other languages
English (en)
French (fr)
Inventor
Yvan Devaux
Daniel R. Wagner
Francisco Azuaje
Melanie Vausort
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luxembourg Institute of Health LIH
Original Assignee
Centre de Recherche Public de la Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre de Recherche Public de la Sante filed Critical Centre de Recherche Public de la Sante
Publication of CA2741117A1 publication Critical patent/CA2741117A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2741117A 2008-10-30 2009-10-30 Biomarkers for heart failure Abandoned CA2741117A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10964908P 2008-10-30 2008-10-30
US61/109,649 2008-10-30
PCT/EP2009/064410 WO2010049538A1 (en) 2008-10-30 2009-10-30 Biomarkers

Publications (1)

Publication Number Publication Date
CA2741117A1 true CA2741117A1 (en) 2010-05-06

Family

ID=41528764

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2741117A Abandoned CA2741117A1 (en) 2008-10-30 2009-10-30 Biomarkers for heart failure

Country Status (9)

Country Link
US (2) US20110294683A1 (enExample)
EP (1) EP2362942B1 (enExample)
JP (1) JP5749171B2 (enExample)
CN (1) CN102203606A (enExample)
BR (1) BRPI0920069A8 (enExample)
CA (1) CA2741117A1 (enExample)
ES (1) ES2640900T3 (enExample)
RU (1) RU2545757C2 (enExample)
WO (1) WO2010049538A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024860A (zh) * 2011-11-08 2014-09-03 佐拉生物科学公司 用于预测接受他汀药物治疗的冠状动脉疾病患者的心血管后果的脂质组学生物标志
US9052328B2 (en) 2011-11-08 2015-06-09 Zora Biosciences Oy Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012014268A (es) 2010-07-09 2013-02-12 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
EP2603622A4 (en) 2010-08-13 2015-04-22 Somalogic Inc BIOMARKERS FOR PANCREATIC CANCER AND USES THEREOF
JP2014207883A (ja) * 2013-03-27 2014-11-06 国立大学法人岡山大学 がん幹細胞及びその用途
WO2014191553A2 (en) * 2013-05-31 2014-12-04 Cobiores Nv Heart failure treatment
EP2843414B1 (en) 2013-08-26 2018-09-19 Roche Diagniostics GmbH Marker for statin treatment stratification in heart failure
CN103487586B (zh) * 2013-09-04 2015-07-15 石家庄洹众生物科技有限公司 一种定量检测可溶性生长刺激表达蛋白2的试验装置
PL228091B1 (pl) * 2014-02-12 2018-02-28 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro
WO2015183601A1 (en) 2014-05-28 2015-12-03 Scripps Health Predictive analysis for myocardial infarction
CN105243294B (zh) * 2015-09-18 2017-06-09 淮南师范学院 一种用于预测癌症病人预后相关的蛋白质对的方法
RU2634375C2 (ru) * 2016-04-18 2017-10-26 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт кардиологии" Способ предупреждения постинфарктного ремоделирования сердца в эксперименте
CA3030038A1 (en) * 2016-07-06 2018-01-11 Guardant Health, Inc. Methods for fragmentome profiling of cell-free nucleic acids
DE102017116204B4 (de) * 2017-07-18 2024-06-27 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration
US11708600B2 (en) * 2017-10-05 2023-07-25 Decode Health, Inc. Long non-coding RNA gene expression signatures in disease diagnosis
JP2022549479A (ja) * 2019-09-30 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー 疾患状態の予測方法
JP7489059B2 (ja) * 2020-04-21 2024-05-23 国立大学法人横浜国立大学 画像生成装置、表示装置、画像生成方法、提示方法およびプログラム
US11854675B1 (en) 2022-10-11 2023-12-26 Flatiron Health, Inc. Machine learning extraction of clinical variable values for subjects from clinical record data
US11915807B1 (en) * 2022-10-11 2024-02-27 Flatiron Health, Inc. Machine learning extraction of clinical variable values for subjects from clinical record data

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513780A (en) * 1999-03-03 2001-09-28 Ludwig Inst Cancer Res Heart abnormalities in vascular endothelial growth factor B (VEGF-B) deficient animals and methods relating to these heart abnormalities
CN1139811C (zh) * 1999-11-09 2004-02-25 赵永同 肿瘤早期检测评估试剂盒及其制备工艺
CN1260492A (zh) * 1999-11-09 2000-07-19 赵永同 肿瘤预后评估试剂盒及其制备工艺
ATE315789T1 (de) * 1999-11-16 2006-02-15 Genentech Inc Elisa für vegf
CA2409948A1 (en) * 2000-05-17 2001-11-22 Xuri Li Methods for detecting for the presence of tumor cells and for screening for anti-tumor agents
WO2003000009A2 (en) * 2001-06-20 2003-01-03 Ludwig Institute For Cancer Research Stimulation of vascularization with vegf-b
CN100401063C (zh) * 2001-08-13 2008-07-09 遗传学发展股份有限公司 选择人类肿瘤最佳疗法的分子诊断和计算机决策辅助系统
US20030096248A1 (en) * 2001-09-04 2003-05-22 Vitivity, Inc. Diagnosis and treatment of vascular disease
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
DE50309809D1 (de) * 2002-11-16 2008-06-19 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
US8632994B2 (en) * 2003-12-01 2014-01-21 Dako Denmark A/S Methods and compositions for immuno-histochemical detection
CN101426489A (zh) * 2004-04-16 2009-05-06 曹义海 抑制血管生成的成分和方法
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024860A (zh) * 2011-11-08 2014-09-03 佐拉生物科学公司 用于预测接受他汀药物治疗的冠状动脉疾病患者的心血管后果的脂质组学生物标志
US9052327B2 (en) 2011-11-08 2015-06-09 Zora Biosciences Oy Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
US9052328B2 (en) 2011-11-08 2015-06-09 Zora Biosciences Oy Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
US9423406B2 (en) 2011-11-08 2016-08-23 Zora Biosciences Oy Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
US9459265B2 (en) 2011-11-08 2016-10-04 Zora Biosciences Oy Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
CN104024860B (zh) * 2011-11-08 2017-06-06 佐拉生物科学公司 用于预测接受他汀药物治疗的冠状动脉疾病患者的心血管后果的脂质组学生物标志
US9863965B2 (en) 2011-11-08 2018-01-09 Zora Biosciences Oy Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment

Also Published As

Publication number Publication date
JP2012507026A (ja) 2012-03-22
BRPI0920069A8 (pt) 2017-10-03
EP2362942B1 (en) 2017-06-21
RU2011121613A (ru) 2012-12-10
US20160188835A1 (en) 2016-06-30
CN102203606A (zh) 2011-09-28
RU2545757C2 (ru) 2015-04-10
EP2362942A1 (en) 2011-09-07
US20110294683A1 (en) 2011-12-01
WO2010049538A1 (en) 2010-05-06
ES2640900T3 (es) 2017-11-07
JP5749171B2 (ja) 2015-07-15
BRPI0920069A2 (pt) 2017-06-06

Similar Documents

Publication Publication Date Title
EP2362942B1 (en) Biomarkers
CN107209184B (zh) 用于诊断多种感染的标记组合及其使用方法
US10704100B2 (en) Biomarkers for heart failure
CN108603887B (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
WO2019099706A1 (en) Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advanced liver fibrosis
US20180100858A1 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
JP2011515666A (ja) トリプルネガティブ乳がんに関連するｄｎａ修復タンパク質およびその使用法
CN117305433A (zh) 用于快速诊断川崎病的分子生物标志物和分析方法
US20180267044A1 (en) Prostate cancer markers and uses thereof
WO2015164616A1 (en) Biomarkers for detection of tuberculosis
US20240044902A1 (en) Methods for the detection and treatment of ovarian cancer
CN106153917B (zh) 两组胰腺癌血浆诊断标志物谱及其应用
CN113444796B (zh) 与肺癌相关的生物标志物及其在诊断癌症中的应用
EP4348262A1 (en) Protein biomarkers for non-alcoholic fatty liver disease (nafld)
CA3233138A1 (en) Lung cancer prediction and uses thereof
US20230408522A1 (en) Multi-protein classifier for detecting early-stage ovarian cancer
CN120809255A (zh) 预测非小细胞肺癌免疫治疗适用性的模型及其应用
WO2026072744A2 (en) Methods of assessing hypertrophic cardiomyopathy
CN121878228A (zh) 一种用于结节性硬化症相关癫痫辅助诊断或评估的生物标志物及其应用
HK40119284A (zh) 一种用於对象预後预测、预後评估和/或治疗方案选择的分子标志物组合及其用途
WO2024123172A1 (en) Protein biomarkers for prognosis of liver fibrosis
CN119876370A (zh) FABP3在预测irAEs中的应用
CN119120680A (zh) Zcchc2在干燥综合征诊断与区分系统性红斑狼疮中的用途
HK40090190A (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
CN113943802A (zh) Golt1b在肾癌的预后中的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141001

FZDE Discontinued

Effective date: 20180821